Hermann Nabi, PhD, HDR, is a regular researcher in the Oncology division at CHU de Québec-Université Laval Research Center and Assistant Professor of Epidemiology at the Department of Social and Preventive Medicine at the Faculty of Medicine of Université Laval. Prior to joining the Center and Université Laval in 2016, Dr. Nabi headed the Research Department of Social and Human Sciences, Epidemiology, Public Health at the Institut National du Cancer(INCa) and was a regular researcher at l’Institut National de la Santé et de la Recherche Médicale(INSERM U.1018) in France.

His team’s work focuses on precision medicine, this emerging medical approach for disease prevention and treatment that takes into account individual differences in genes, environment and lifestyle for each person. With advances in genomics and the advent of new molecular biology technologies, precision medicine is attracting a lot of attention and has become an area of ​​strong international competition. However, despite the large volume and unprecedented rate of gene or biomarker discoveries, relatively few have reached the bedside or contributed to improving the health of populations. This relative poor performance could be explained by the fact that only a small proportion (about 3%) of all published global research addresses issues related to the integration of genomics innovations into health and disease prevention. For this reason, the ultimate goal of Dr. Nabi’s team is to generate evidence to facilitate a successful and responsible integration of precision medicine innovations into health care and prevention, particularly for cancer.

To achieve this goal, his work is organized around three main objectives:

1) Characterize the mechanisms and organizational implications of the progressive adoption of innovations in precision medicine in oncology,

2) Evaluate the impact of diagnostic and therapeutic innovations in precision medicine on the quality of life and clinical outcomes of cancer patients and the effectiveness for the health system,

3) Develop and evaluate intervention methods to support the integration of innovations, which takes into account patients and populations’ preferences, economic, accessibility and impact issues, in a knowledge transfer perspective.

The originality of this research program lies in its interdisciplinary approach, which combines a variety of skills and methodological tools to answer questions that are at the interface of several scientific fields. This approach proposes a new way of approaching translational research (the transfer of discoveries from laboratory to bedside), through the use of concepts, models and methods  the human and social sciences, epidemiology, public health, health services research and implementation science.

Hôpital Saint-Sacrement
1050, Chemin Ste-Foy
J0-01
Québec, Qc
Canada G1S 4L8
108 entries « 1 of 11 »

Mc Brearty C, Bisaillon L, Dorval M, Nabi H, Desbiens C, Lemieux J, Théberge V, Baghdadli A, Lauzier S, Savard J

Disruptions in Cancer Care Due to the COVID-19 Pandemic and Fear of Cancer Recurrence in Women with Breast Cancer: A Mixed-Methods Study

Journal Article

Curr Oncol, 31 (2), 2024.

Abstract | Links:

Mbuya-Bienge C, Pashayan N, Kazemali CD, Lapointe J, Simard J, Nabi H

A Systematic Review and Critical Assessment of Breast Cancer Risk Prediction Tools Incorporating a Polygenic Risk Score for the General Population

Journal Article

Cancers (Basel), 15 (22), 2023.

Abstract | Links:

Ouellet J, Lapointe J, Raîche C, Guerin A, Helal S, Fitzpatrick J, Dorval M, Nabi H

Scope of coverage of medical genetics and genomics in pre-clerkship programs of Canadian faculties of medicine: A curriculum analysis

Journal Article

Am J Med Genet A, 191 (1), 2023.

Abstract | Links:

Audet S, Doyle C, Lemieux C, Tardif MA, Gauvreau A, Simonyan D, Nabi H, Lemieux J

Adherence to CONSORT Guidelines and Reporting of the Determinants of External Validity in Clinical Oncology Randomized Controlled Trials: A Review of Trials Published in Four Major Journals between 2013 and 2015

Journal Article

Curr Oncol, 30 (2), 2023.

Abstract | Links:

Moreno PG, Knoppers T, Zawati MH, Lang M, Knoppers BM, Wolfson M, Nabi H, Dorval M, Simard J, Joly Y

Regulating cancer risk prediction: legal considerations and stakeholder perspectives on the Canadian context

Journal Article

Hum Genet, 142 (7), 2023.

Abstract | Links:

Lapointe J, Côté JM, Mbuya-Bienge C, Dorval M, Pashayan N, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Brooks JD, Walker MJ, Blackmore KM, Joly Y, Knoppers BM, Chiarelli AM, Simard J, Nabi H

Canadian Healthcare Professionals' Views and Attitudes toward Risk-Stratified Breast Cancer Screening

Journal Article

J Pers Med, 13 (7), 2023.

Abstract | Links:

Ayoub A, Lapointe J, Nabi H, Pashayan N

Risk-Stratified Breast Cancer Screening Incorporating a Polygenic Risk Score: A Survey of UK General Practitioners' Knowledge and Attitudes

Journal Article

Genes (Basel), 14 (3), 2023.

Abstract | Links:

Hébert J, Bergeron AS, Veillette AM, Bouchard K, Nabi H, Dorval M

Issues associated with a hereditary risk of cancer: Knowledge, attitudes and practices of nurses in oncology settings

Journal Article

Can Oncol Nurs J, 32 (2), 2022.

Abstract | Links:

Hébert J, Bergeron AS, Veillette AM, Bouchard K, Nabi H, Dorval M

Enjeux associés au risque héréditaire de cancer: connaissances, attitudes et pratiques infirmières en oncologie

Journal Article

Can Oncol Nurs J, 32 (2), 2022.

| Links:

Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, Nabi H, Joly Y

Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges

Journal Article

Crit Rev Oncol Hematol, 178 , 2022.

Abstract | Links:

108 entries « 1 of 11 »
Signaler des ajouts ou des modifications

Active projects

  • Optimiser l’application des approches de médecine de précision dans la prévention et le traitement des cancers, from 2023-07-01 to 2026-06-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2025-09-30
  • Personalized risk-stratified breast cancer follow-up care: a feasibility and acceptability study, from 2023-06-26 to 2026-06-30
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2025-03-31
  • Projet de démonstration de la valeur ajoutée d’une signature génomique de seconde génération dans la prise en charge de patients atteints de cancer du sein de stade précoce en contexte clinique réel québécois, from 2024-04-01 to 2026-03-31
  • The Pan-Canadian Genome Library (PCGL), from 2023-07-01 to 2030-03-31
  • Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2025-03-31

Recently finished projects

  • Enjeux de l’intégration de la Médecine de Précision en Oncologie : mieux comprendre pour mieux agir (teMPO), from 2018-07-01 to 2022-06-30
  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2023-10-27
Data provided by the Université Laval research projects registery